DRUGS & SUPPLEMENTS
What do you feel about the cost of the medicine? Is it expensive?
Metocare is a cardioselective beta1-blocker without intrinsic sympathomimetic activity. This medication has antihypertensive, antianginal and antiarrhythmic effect. Metocare decreases automaticity of sinus node, reducing heart rate, slows AV-conduction, decreases myocardial contractility and excitability, reduces cardiac output, reduces myocardial oxygen demand. This drug inhibits the stimulatory effect of catecholamines on the heart during physical and psycho-emotional stress.
Metocare causes a hypotensive effect which is stabilized by the end of the second week of a course. With angina Metocare reduces the frequency and severity of attacks.
This medicine also normalizes the heart rate during supraventricular tachycardia and atrial fibrillation; when myocardial infarction it contributes to limit the zone of ischemia of the heart muscle and reduces the risk of developing fatal arrhythmias, reduces the risk of recurrence of myocardial infarction. When Metocare is used in the medium therapeutic doses it has a less pronounced effect on smooth muscles of the bronchi and peripheral arteries than non-selective beta-blockers.
After oral administration Metocare is rapidly and almost completely absorbed from the gastrointestinal tract, Cmax of the active substance in the blood plasma is reached after 1-2 hours. This medication intensively metabolized in the liver to form inactive metabolites. T1/2 of Metocare from plasma is 3-4 h and during the course of treatment it does not change. More than 95% of the dose excreted by the kidneys of which only 3% is in unchanged form.
Hypertension, prevention of angina, cardiac arrhythmias, secondary prevention after myocardial infarction, cardiac hyperkinetic syndrome (including in hyperthyroidism, NDCs). Prophylaxis of migraine.
For oral administration the average dose of Metocare is 100 mg / day in 1-2 reception. If necessary the daily dose gradually increased up to 200 mg. For IV injections a single dose is 2.5 mg, with no effect a re-introduction is possible in 5 minutes.
Maximum daily dose for oral administration is 400 mg, for IV injections a single dose is 15-20 mg.
Cardiovascular system: possible bradycardia, hypotension, AV-conduction disturbances, symptoms of heart failure.
Digestive system: at the beginning of therapy may include dry mouth, nausea, vomiting, diarrhea, constipation, and in some cases - liver function abnormalities.
CNS and peripheral nervous system: at the beginning of therapy may be weakness, fatigue, dizziness, headache, muscle cramps, coldness and paresthesia in the extremities; possible reduction in the secretion of tear fluid, conjunctivitis, rhinitis, depression, sleep disturbances, nightmares.
Hemopoietic system: in some cases - thrombocytopenia.
Endocrine: hypoglycemic state in patients with diabetes.
Respiratory system: in predisposed patients may cause symptoms of bronchial obstruction.
Allergic reactions: skin rash, itching.
AV-block II and III degree, sinoatrial block, bradycardia, SSS, hypotension, chronic heart failure IIB-III stages, acute heart failure, cardiogenic shock, metabolic acidosis, pronounced disturbances of peripheral circulation, increased sensitivity to Metocare.
Taking of Metocare during pregnancy is only possible if the intended benefits to the mother outweighs the potential risk to the fetus. This medication crosses the placental barrier. In connection with the possible development of a newborn bradycardia, hypotension, hypoglycemia, and respiratory failure, Metocare should be abolished for 48-72 hours before the scheduled date of delivery. After delivery it is necessary to ensure strict monitoring of the newborn within 48-72 hours.
Metocare in small amounts excreted in breast milk. The using during lactation is not recommended.
With careful use in patients with chronic obstructive airways disease, diabetes, Raynaud's disease and obliterative peripheral arterial disease, pheochromocytoma (to be used in combination with alpha-blockers), pronounced renal and liver functions impairment.
During treatment with Metocare a production of lacrimal fluid may decreases, which is important for patients who use contact lenses.
Completion of a long course of treatment with Metocare should be gradual (at least 10 days) under the supervision of a physician.
There is not recommended for concurrent use of Metocare with MAO inhibitors.
Combined therapy with clonidine should receive the later stop in a few days after discontinuation of Metocare, in order to avoid a hypertensive crisis. Simultaneous administration of Metocare with hypoglycemic agents require correction of their dosing regimen.
A few days before the anesthesia it is necessary to stop taking this drug or find any anesthesia medication with minimal negative inotropic effects.
Patients whose work requires more attention, the application of Metocare outpatients should be addressed only after the evaluation of individual patient response.
Sympatholytics, nifedipine, nitroglycerin, diuretics, hydralazine and other antihypertensive drugs potentiate hypotension.
Antiarrhythmic and anesthetic medications increase the risk of bradycardia, arrhythmia, hypotension.
Digitalis drugs potentiate slowing AV conduction.
Simultaneously intravenous injection of verapamil and diltiazem may cause cardiac arrest.
Beta-adrenoceptor agonists, aminophylline, cocaine, estrogens, indomethacin and other NSAIDs impair antihypertensive effect.
Metocare enhances and prolongs the action of anti depolarizing muscle relaxants.
Combination with alcohol leads to mutual reinforcement of inhibitory effects on the CNS.
Allergens increased the risk of severe systemic allergic reactions or anaphylaxis.
Metocare edits the effectiveness of insulin and oral antidiabetic drugs and increases the risk of hypoglycemia.
Oral contraceptives, cimetidine, ranitidine, phenothiazines raise the level of this drug in the blood, rifampicin decreases it.
Metocare reduces the clearance of lidocaine, the effectiveness of beta 2-agonists (it is necessary to increase the dose of the latter).
This medicine is incompatible with MAO inhibitors of type A.
Symptoms: hypotension, acute heart failure, bradycardia, heart block, AV block, cardiogenic shock, bronchospasm, trouble breathing and consciousness, coma, nausea, vomiting, generalized convulsions, cyanosis (manifest in 20 minutes - 2 hours after taking of Metocare).
Treatment: gastric lavage, the symptomatic therapy: atropine sulfate injection (IV fast 0.5-2 mg) if bradycardia and a violation of AV conduction; glucagon (1-10 mg IV, then IV infusion 2-2.5 mg / h) and dobutamine in the case of reduction of myocardial contractility; agonists (noradrenaline, adrenaline, etc.) when arterial hypotension; diazepam (IV slowly) to eliminate seizures; beta-agonists inhalation or IV jet injection of aminophylline to relieve broncho spastic reactions; cardioacceleration.
Depending on the reaction of the Metocare after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Metocare not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Metocare addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology